Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer

scientific article published on 21 March 2019

Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1112926652
P356DOI10.1186/S13058-019-1127-Y
P932PMC publication ID6429830
P698PubMed publication ID30898150

P50authorDavid CroucherQ58447784
D Neil WatkinsQ88619019
Sharissa L LathamQ40325796
P2093author name stringElgene Lim
Walter Kolch
Thomas R Cox
Sean P Kennedy
Neil Portman
Paul Timpson
Darren N Saunders
Max Nobis
Kendelle J Murphy
Robert F Shearer
Amaya Garcia Munoz
Antonia L Cadell
Gabriella R Marriott
Jeremy Z R Han
Yolande E I O'Donnell
James T Williams
Jordan F Hastings
Dushan Miladinovic
P2860cites workAn allosteric mechanism for activation of the kinase domain of epidermal growth factor receptorQ24293598
Mechanism of activation and inhibition of the HER4/ErbB4 kinaseQ24310089
The protein kinase complement of the human genomeQ24324497
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.Q45945230
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.Q48055457
Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challengesQ49887925
Bimolecular complementation affinity purification (BiCAP) reveals dimer-specific protein interactions for ERBB2 dimers.Q51646294
A dimerization motif for transmembrane α–helicesQ54246480
Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis.Q55261407
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline UpdateQ57106143
Nerve Growth Factor Cooperates with p185HER2in Activating Growth of Human Breast Carcinoma CellsQ62604220
Multistrip western blotting to increase quantitative data outputQ83684729
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast CancerQ88502132
Cell signaling by receptor tyrosine kinasesQ24598357
Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomesQ24630783
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferationQ24678674
Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamilyQ27654013
Lapatinib plus capecitabine for HER2-positive advanced breast cancerQ27851403
Trastuzumab emtansine for HER2-positive advanced breast cancerQ27851917
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerQ27853134
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneQ27860693
Untangling the ErbB signalling networkQ27860884
The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor FamilyQ28073335
The cellular response to neuregulins is governed by complex interactions of the erbB receptor familyQ28609130
COT drives resistance to RAF inhibition through MAP kinase pathway reactivationQ29615032
Gab2 regulates cytoskeletal organization and migration of mammary epithelial cells by modulating RhoA activationQ30497820
Detecting protein-protein interactions with a green fluorescent protein fragment reassembly trap: scope and mechanism.Q31138784
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complexQ34314489
VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancerQ35112894
Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancerQ35742383
Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737Q35779325
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancerQ37633741
Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patientsQ38809615
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trialQ38953228
Involvement of Lyn and the atypical kinase SgK269/PEAK1 in a basal breast cancer signaling pathwayQ39200111
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptorsQ39355055
Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivationQ39528062
Pertuzumab and trastuzumab: the rationale way to synergyQ39701009
All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells.Q39941394
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapyQ39960692
Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer researchQ40445359
ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors.Q40966152
Specificity within the EGF family/ErbB receptor family signaling networkQ41721612
HER-2/neu oncogene protein and prognosis in breast cancerQ41927421
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete responseQ42677733
High-sensitivity measurements of multiple kinase activities in live single cellsQ42735283
The single transmembrane domains of ErbB receptors self-associate in cell membranesQ43821697
Evidence for new homotypic and heterotypic interactions between transmembrane helices of proteins involved in receptor tyrosine kinase and neuropilin signalingQ44023503
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growthQ44120544
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P4510describes a project that usesImageJQ1659584
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectErb-b2 receptor tyrosine kinase 2Q415271
pertuzumabQ1998021
protein heterodimerization activityQ14762999
P304page(s)43
P577publication date2019-03-21
P1433published inBreast Cancer ResearchQ2208481
P1476titleTargeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer
P478volume21

Reverse relations

cites work (P2860)
Q92782594An Optimised Protocol Harnessing Laser Capture Microdissection for Transcriptomic Analysis on Matched Primary and Metastatic Colorectal Tumours
Q96228738Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma
Q100751537Attenuation of p53 mutant as an approach for treatment Her2-positive cancer
Q91694832circMAN1A2 could serve as a novel serum biomarker for malignant tumors

Search more.